 I-Mab NASDAQ: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 12 clinical study in China to evaluate I-Mabs proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors CTR20200445; NCT04322006. 